Reply to N. Fazio.
作者信息
O'Reilly Eileen M, Park Wungki, Kelsen David P
机构信息
Eileen M. O'Reilly, MD; Wungki Park, MD; and David P. Kelsen, MD, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.
出版信息
J Clin Oncol. 2020 Jul 20;38(21):2467-2468. doi: 10.1200/JCO.20.00833. Epub 2020 May 14.
Abstract
摘要
相似文献
1
Reply to N. Fazio.回复N. 法齐奥。
J Clin Oncol. 2020 Jul 20;38(21):2467-2468. doi: 10.1200/JCO.20.00833. Epub 2020 May 14.
2
Cisplatin Plus Gemcitabine as Standard of Care for Germline -Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?顺铂联合吉西他滨作为胚系突变型胰腺腺癌的标准治疗方案：我们进展得太快了吗？
J Clin Oncol. 2020 Jul 20;38(21):2466-2467. doi: 10.1200/JCO.20.00419. Epub 2020 May 14.
3
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation.随机、多中心、Ⅱ期临床试验：吉西他滨和顺铂联合或不联合维利帕利治疗胰腺导管腺癌和种系突变患者。
J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.
4
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.每两周一次的低剂量序贯吉西他滨、5-氟尿嘧啶、亚叶酸钙和顺铂（GFP）：一种用于外分泌型胰腺转移性腺癌的高效新型疗法。
Cancer Invest. 2003;21(4):489-96. doi: 10.1081/cnv-120022357.
5
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.体内治疗反应取决于肿瘤的范可尼贫血/BRCA2状态。
Clin Cancer Res. 2005 Oct 15;11(20):7508-15. doi: 10.1158/1078-0432.CCR-05-1048.
6
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.BRCA2 基因突变携带者转移性胰腺腺癌患者接受顺铂为基础的治疗后达到完全缓解。
Cancer Biol Ther. 2011 Aug 1;12(3):165-8. doi: 10.4161/cbt.12.3.16292.
7
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.同源重组缺陷型胰腺导管腺癌的基因组特征与分类。
Gastroenterology. 2021 May;160(6):2119-2132.e9. doi: 10.1053/j.gastro.2021.01.220. Epub 2021 Jan 30.
8
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.吉西他滨、顺铂和持续输注氟尿嘧啶用于晚期胰腺癌的II期研究。
J Clin Oncol. 2003 Aug 1;21(15):2920-5. doi: 10.1200/JCO.2003.03.022.
9
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.吉西他滨固定剂量率联合顺铂治疗胰腺转移性腺癌的II期研究。
J Clin Oncol. 2006 Jan 20;24(3):379-85. doi: 10.1200/JCO.2005.01.8267. Epub 2005 Dec 12.
10
Cutaneous apocrine adenocarcinoma in a PALB2 germline pathogenic variant carrier.携带PALB2种系致病变异的皮肤大汗腺癌。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e636-e638. doi: 10.1111/jdv.18094. Epub 2022 Mar 28.
引用本文的文献
1
Importance of mutation for the current treatment of pancreatic cancer beyond maintenance.对于目前除维持治疗以外的胰腺癌治疗，突变的重要性。
World J Gastroenterol. 2021 Oct 21;27(39):6515-6521. doi: 10.3748/wjg.v27.i39.6515.
本文引用的文献
1
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.DNA损伤反应通路存在基因突变的胰腺腺癌患者的预后：“了解你的肿瘤”项目的结果
JCO Precis Oncol. 2019 Dec;3:1-10. doi: 10.1200/PO.19.00115.
2
Cisplatin Plus Gemcitabine as Standard of Care for Germline -Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?顺铂联合吉西他滨作为胚系突变型胰腺腺癌的标准治疗方案：我们进展得太快了吗？
J Clin Oncol. 2020 Jul 20;38(21):2466-2467. doi: 10.1200/JCO.20.00419. Epub 2020 May 14.
3
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation.随机、多中心、Ⅱ期临床试验：吉西他滨和顺铂联合或不联合维利帕利治疗胰腺导管腺癌和种系突变患者。
J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.
4
Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer.维持奥拉帕利治疗种系突变转移性胰腺癌。
N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.
5
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.BRCA1/2 突变型和三阴性乳腺癌 BRCA 样亚组中的卡铂：TNT 试验。
Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
6
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.BRCA1和BRCA2突变使源自患者的胰腺癌异种移植瘤对化疗敏感。
Br J Cancer. 2015 Jul 28;113(3):425-32. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.
7
Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.顺铂、奥沙利铂和卡铂在体外均能抑制 mRNA 翻译。
Toxicol Lett. 2014 Feb 10;225(1):43-7. doi: 10.1016/j.toxlet.2013.11.015. Epub 2013 Nov 23.
8
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
9
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.FOLFOX-6方案作为局部晚期和/或转移性胰腺癌的一线治疗方案。
Am J Clin Oncol. 2007 Feb;30(1):15-20. doi: 10.1097/01.coc.0000235997.18657.a6.
10
Oxaliplatin-induced damage of cellular DNA.奥沙利铂诱导的细胞DNA损伤。
Mol Pharmacol. 2000 Nov;58(5):920-7. doi: 10.1124/mol.58.5.920.
Zotero 插件